Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Sclar, David Alexander
1998.
Pharmaceutical economics & health policy.
Clinical Therapeutics,
Vol. 20,
Issue. 2,
p.
326.
Knapp, MRJ
1998.
Measuring the economic benefit of treatment with atypical antipsychotics.
European Psychiatry,
Vol. 13,
Issue. ,
p.
37s.
Craig, Neil
and
Stark, Cameron
1998.
Authors' reply.
Psychiatric Bulletin,
Vol. 22,
Issue. 3,
p.
186.
Amin, S
Tolley, K
and
Harrison, G
1998.
Improving quality in economic evaluations of the management of schizophrenia.
Journal of Medical Economics,
Vol. 1,
Issue. 1-4,
p.
163.
Knapp, MRJ
1998.
Measuring the economic benefit of treatment with atypical antipsychotics.
European Psychiatry,
Vol. 13,
Issue. S1,
p.
37s.
Thomas, Kayl
1998.
Best Practice Outcomes for Schizophrenia: Does Measurement of Medication Compliance Provide a Key?.
Australasian Psychiatry,
Vol. 6,
Issue. 6,
p.
306.
Percudani, Mauro
and
Knapp, Martin
1998.
The economic perspective in the care and treatment of patients with diagnosis of schizophrenia.
Epidemiologia e Psichiatria Sociale,
Vol. 7,
Issue. 3,
p.
197.
1998.
Risperidone and clozapine were more cost effective than haloperidol and chlorpromazine in patients with schizophrenia.
Evidence Based Mental Health,
Vol. 1,
Issue. 2,
p.
64.1.
Haro, Josep Maria
Salvador-Carulla, Luis
Cabasés, Juan
Madoz, Vicente
and
Vázquez-Barquero, José Luis
1998.
Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain.
British Journal of Psychiatry,
Vol. 173,
Issue. 4,
p.
334.
Percudani, M.
Fattore, G.
Galletta, J.
Mita, P. L.
Contini, A.
and
Altamura, A. C.
1999.
Health care costs of therapy‐refractory schizophrenic patients treated with clozapine: a study in a community psychiatric service in Italy.
Acta Psychiatrica Scandinavica,
Vol. 99,
Issue. 4,
p.
274.
Burgess, Philip
and
Pirkis, Jane
1999.
The currency of case management: benefits and costs.
Current Opinion in Psychiatry,
Vol. 12,
Issue. 2,
p.
195.
Landén, Mikael
Grenfeldt, Bengt
Davidsson, Pia
Stridsberg, Mats
Regland, Björn
Gottfries, Carl-Gerhard
and
Blennow, Kaj
1999.
Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia.
European Neuropsychopharmacology,
Vol. 9,
Issue. 4,
p.
311.
Westrin, Claes-Göran
1999.
Evaluating quality of mental health care.
Current Opinion in Psychiatry,
Vol. 12,
Issue. 2,
p.
201.
Lecompte, Damien
and
Cookson, Ron F
1999.
The economic value of atypical antipsychotics: A comparison of risperidone and olanzapine revisited.
International Journal of Psychiatry in Clinical Practice,
Vol. 3,
Issue. 1,
p.
3.
Gilbody, Simon M
and
Petticrew, Mark
1999.
Rational decision-making in mental health: the role of systematic reviews.
The Journal of Mental Health Policy and Economics,
Vol. 2,
Issue. 3,
p.
99.
Lawrie, Stephen M
Whalley, Heather
Kestelman, Julia N
Abukmeil, Suheib S
Byrne, Majella
Hodges, Ann
Rimmington, J Ewen
Best, Jonathan JK
Owens, David GC
and
Johnstone, Eve C
1999.
Magnetic resonance imaging of brain in people at high risk of developing schizophrenia.
The Lancet,
Vol. 353,
Issue. 9146,
p.
30.
Schuitz, Susan K
and
Andreasen, Nancy C
1999.
Schizophrenia.
The Lancet,
Vol. 353,
Issue. 9162,
p.
1425.
Landén, Mikael
Davidsson, Pia
Gottfries, Carl-Gerhard
Stridsberg, Bengt GrenfeldtMats
and
Blennow, Kaj
1999.
Reduction of the small synaptic vesicle protein synaptophysin but not the large dense core chromogranins in the left thalamus of subjects with schizophrenia.
Biological Psychiatry,
Vol. 46,
Issue. 12,
p.
1698.
Haddad, Peter
and
Knapp, Martin
2000.
Health professionals' views of services for schizophrenia – fragmentation and inequality.
Psychiatric Bulletin,
Vol. 24,
Issue. 2,
p.
47.
Waddington, John L.
and
Quinn, John F.
2000.
Atypical Antipsychotics.
p.
19.
eLetters
No eLetters have been published for this article.